Inogen (NASDAQ:INGN - Get Free Report) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Friday.
Separately, Needham & Company LLC reissued a "hold" rating on shares of Inogen in a report on Friday, November 8th.
Read Our Latest Stock Report on Inogen
Inogen Price Performance
INGN traded up $0.17 during trading hours on Friday, reaching $8.48. 183,204 shares of the stock traded hands, compared to its average volume of 318,450. Inogen has a fifty-two week low of $5.08 and a fifty-two week high of $13.33. The company has a market cap of $201.98 million, a price-to-earnings ratio of -3.77 and a beta of 1.02. The firm's fifty day simple moving average is $9.46 and its two-hundred day simple moving average is $9.72.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. acquired a new position in Inogen in the second quarter worth about $30,000. Quarry LP bought a new position in Inogen during the 3rd quarter worth approximately $59,000. Verition Fund Management LLC acquired a new position in shares of Inogen in the 3rd quarter worth approximately $106,000. Virtu Financial LLC bought a new stake in shares of Inogen in the 3rd quarter valued at approximately $111,000. Finally, Paloma Partners Management Co acquired a new stake in shares of Inogen during the 3rd quarter valued at approximately $126,000. 89.94% of the stock is owned by institutional investors and hedge funds.
Inogen Company Profile
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
